Top 10 Performing Stocks For 2019

General Electric (GE) has had a tumultuous year, yet should not be dismissed as an investment, despite the plunge its share price has undergone.

How has this venerable blue-chip stock fallen 45.39% from its 52-week high of $32.04? A number of factors have hit General Electric in the past few months. The first major issue was the third quarter performance report showed that EPS was projected to be $1.05-1.10, down from the estimated $1.60-1.70 that was reported in the second quarter. While most of General Electric’s segments were actually performing well, the power generation segment was weak, and the oil and gas segment was compromised by weakness in its markets, and this weakness led to the earnings outlook being slashed.

Top 10 Performing Stocks For 2019: Graco Inc.(GGG)

Advisors’ Opinion:

  • [By Max Byerly]

    Graco Inc. (NYSE:GGG) has been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat reports. Eleven analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $49.04.

  • [By Joseph Griffin]

    Graco Inc. (NYSE:GGG) – Analysts at William Blair lowered their Q1 2019 earnings per share (EPS) estimates for Graco in a research report issued to clients and investors on Tuesday, January 29th. William Blair analyst N. Heymann now forecasts that the industrial products company will post earnings per share of $0.49 for the quarter, down from their previous forecast of $0.51. William Blair also issued estimates for Graco’s Q4 2019 earnings at $0.44 EPS and FY2020 earnings at $2.18 EPS.

  • [By Shane Hupp]

    Zacks Investment Management acquired a new stake in Graco Inc. (NYSE:GGG) in the second quarter, HoldingsChannel.com reports. The fund acquired 5,096 shares of the industrial products company’s stock, valued at approximately $230,000.

Top 10 Performing Stocks For 2019: Pretium Resources, Inc.(PVG)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    A handful of gold stocks were soaring by double digits today. Shares of Pretium Resources (NYSE:PVG) paced the peer group with intra-day gains as high as 13.1%. That was followed by an increase of as much as 11% in shares of AngloGold Ashanti (NYSE:AU), helped by strong full-year 2018 earnings reported earlier in the day, and more than a 10% rise in Sibanye-Stillwater (NYSE:SBGL) stock.

  • [By Max Byerly]

    Pretium Resources Inc (TSE:PVG) (NYSE:PVG) Director Robert Allan Quartermain sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of C$12.07, for a total value of C$603,500.00.

  • [By Dan Caplinger]

    Wednesday was a down day for the stock market, with the Dow Jones Industrial Average posting triple-digit losses even as broader benchmarks had much smaller moves. Market participants largely focused their attention on the inflation front, as March consumer price index numbers showed a 0.2% rise in the core rate excluding food and energy. Year-over-year price changes have accelerated, seemingly giving the Federal Reserve more justification to continue raising interest rates. Yet even though many stocks generally react unfavorably to inflation fears, there were some big gainers that had good news. Hilton Worldwide Holdings (NYSE:HLT), Pretium (NYSE:PVG), and Applied Optoelectronics (NASDAQ:AAOI) were among the best performers on the day. Here’s why they did so well.

Top 10 Performing Stocks For 2019: TriCo Bancshares(TCBK)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on TriCo Bancshares (TCBK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on TriCo Bancshares (TCBK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    News articles about TriCo Bancshares (NASDAQ:TCBK) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TriCo Bancshares earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the financial services provider an impact score of 46.135433392334 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Logan Wallace]

    TriCo Bancshares (NASDAQ:TCBK) and FB Financial (NYSE:FBK) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Top 10 Performing Stocks For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Max Byerly]

    Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod (finance.yahoo.com) Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains (seekingalpha.com) Merrimack Pharmaceuticals’ (MACK) “Hold” Rating Reaffirmed at Robert W. Baird (americanbankingnews.com) Merrimack Crashes as Phase II Pancreatic Cancer Study Fails (zacks.com) MM-141 (benzinga.com)

    Several equities analysts have commented on MACK shares. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Wednesday, April 25th. JPMorgan Chase & Co. downgraded Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Monday. Robert W. Baird cut their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

  • [By Max Byerly]

    Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) by 22.0% in the second quarter, HoldingsChannel.com reports. The fund owned 174,774 shares of the biopharmaceutical company’s stock after acquiring an additional 31,509 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Merrimack Pharmaceuticals were worth $858,000 as of its most recent filing with the SEC.

  • [By Shane Hupp]

    Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares reached a new 52-week low on Thursday . The stock traded as low as $4.56 and last traded at $4.71, with a volume of 33598 shares. The stock had previously closed at $4.74.

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

Top 10 Performing Stocks For 2019: KB Financial Group Inc(KB)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    As a result, we’ve been able to identify deeply undervalued companies while no one is looking – such as KB Financial Group Inc. (NYSE: KB), a wealth management firm based in Seoul.

  • [By Ethan Ryder]

    KB Financial Group, Inc. (NYSE:KB) saw a large decrease in short interest in August. As of August 15th, there was short interest totalling 324,037 shares, a decrease of 40.6% from the July 31st total of 545,627 shares. Based on an average daily volume of 128,119 shares, the short-interest ratio is presently 2.5 days.

  • [By Matthew Frankel, CFP®, Sean Williams, and Jordan Wathen]

    However, there may still be some bargains to be found. Here’s why three of our contributors think it may be time to take a look at Synchrony Financial (NYSE:SYF), KB Financial Group (NYSE:KB), and Discover Financial Services (NYSE:DFS).

Top 10 Performing Stocks For 2019: Oclaro, Inc.(OCLR)

Advisors’ Opinion:

  • [By ]

    Oclaro (OCLR) : “No, I don’t like anything optical. I’d go with Cisco Systems (CSCO) .”

    Stratasys (SSYS) : “If you want 3D printing, you want HP (HPQ) .”

  • [By Anders Bylund]

    Shares of Oclaro (NASDAQ:OCLR) gained 33.3% in March of 2018, according to data from S&P Global Market Intelligence, riding a generous buyout premium as longtime rival Lumentum (NASDAQ:LITE) launched a takeover bid. On the flip side, many other companies in the fiber-optic networking market saw their share prices shrink last month — largely because of a lack of Oclaro-style buyout attention for those companies.

  • [By Max Byerly]

    ValuEngine upgraded shares of Oclaro (NASDAQ:OCLR) from a hold rating to a buy rating in a research report released on Thursday morning.

    Several other research firms have also issued reports on OCLR. Jefferies Group lowered Oclaro from a buy rating to a hold rating and set a $6.50 price target on the stock. in a research report on Friday, February 2nd. Cowen restated a buy rating and set a $8.00 price target on shares of Oclaro in a research report on Tuesday, February 6th. B. Riley reduced their price target on Oclaro from $10.00 to $9.50 and set a neutral rating on the stock in a research report on Wednesday, May 9th. Zacks Investment Research upgraded Oclaro from a sell rating to a hold rating in a research report on Tuesday, May 15th. Finally, DA Davidson reduced their price target on Oclaro from $11.00 to $9.00 and set a buy rating on the stock in a research report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $10.55.

  • [By Shane Hupp]

    Thompson Siegel & Walmsley LLC reduced its stake in Oclaro Inc. (NASDAQ:OCLR) by 58.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,246,272 shares of the semiconductor company’s stock after selling 1,729,354 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.74% of Oclaro worth $11,914,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Money Morning News Team]

    Oclaro Inc. (Nasdaq: OCLR) is a Silicon Valley-based semiconductor equipment company. It is a designer, manufacturer, and marketer of modules, optical components, and subsystems for data center, metro, and long-haul markets worldwide.

  • [By Lisa Levin] Gainers
    Acacia Communications, Inc. (NASDAQ: ACIA) shares rose 18.3 percent to $37.25 in pre-market trading after gaining 1.74 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) rose 12.1 percent to $2.69 in pre-market trading after surging 4.80 percent on Friday.
    NXP Semiconductors N.V. (NASDAQ: NXPI) rose 10.9 percent to $109.75 in pre-market trading after Bloomberg reported that the China’s Commerce Ministry has restarted its review of QUALCOMM Incorporated’s (NASDAQ: QCOM) proposed takeover of NXP Semiconductors.
    Renewable Energy Group, Inc. (NASDAQ: REGI) rose 10.6 percent to $15.20 in pre-market trading. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
    NeoPhotonics Corporation (NYSE: NPTN) rose 10 percent to $6.40 in pre-market trading.
    Vaxart, Inc. (NASDAQ: VXRT) shares rose 8 percent to $5.54 in pre-market trading after gaining 2.19 percent on Friday.
    Profire Energy, Inc. (NASDAQ: PFIE) rose 7.3 percent to $4.58 in pre-market trading after gaining 6.22 percent on Friday.
    Marvell Technology Group Ltd. (NASDAQ: MRVL) rose 7 percent to $22.49 in pre-market trading after falling 1.96 percent on Friday.
    Oclaro, Inc. (NASDAQ: OCLR) shares rose 6.9 percent to $9.16 in pre-market trading.
    TransEnterix, Inc. (NYSE: TRXC) rose 5.7 percent to $2.24 in pre-market trading after gaining 3.92 percent on Friday.
    CVR Refining, LP (NYSE: CVRR) rose 5.4 percent to $19.70 in pre-market trading.
    Federal Agricultural Mortgage Corporation (NYSE: AGM) rose 5.2 percent to $92.95 in pre-market trading.
    International Game Technology PLC (NYSE: IGT) rose 5.2 percent to $29.94 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares rose 5.1 percent to $66.30 in the pre-market trading session.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5 percent to $10.70 in pre-market trading after climbing 15.66 percent on Friday.
    Finisar

Top 10 Performing Stocks For 2019: Washington Real Estate Investment Trust(WRE)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Washington Real Estate Investment Trust (NYSE:WRE) have been assigned an average rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.33.

  • [By Max Byerly]

    Colony Group LLC cut its stake in shares of Washington Real Estate Investment Trust (NYSE:WRE) by 8.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,266 shares of the real estate investment trust’s stock after selling 2,410 shares during the period. Colony Group LLC’s holdings in Washington Real Estate Investment Trust were worth $797,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Washington Real Estate Investment Trust (WRE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Dan Caplinger]

    The stock market lost ground on Monday, as investors appeared to have second thoughts about the future of the U.S. economy even as trade negotiations with China appear to be going well. The Dow Jones Industrial Average had been down by more than 400 points earlier in the session before recovering to finish lower by just 207, and broader benchmarks saw more modest declines on a percentage basis. Even amid the carnage, there was some good news for certain companies. Washington Real Estate Investment Trust (NYSE:WRE), Ascendis Pharma (NASDAQ:ASND), and Bluegreen Vacations (NYSE:BXG) were among the top performers. Here’s why they did so well.

  • [By Shane Hupp]

    Tocqueville Asset Management L.P. purchased a new stake in Washington Real Estate Investment Trust (NYSE:WRE) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,205 shares of the real estate investment trust’s stock, valued at approximately $219,000.

Top 10 Performing Stocks For 2019: Fiserv, Inc.(FISV)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Fiserv (NASDAQ:FISV)’s share price hit a new 52-week high and low during trading on Thursday . The company traded as low as $76.14 and last traded at $74.93, with a volume of 49348 shares traded. The stock had previously closed at $75.96.

  • [By Max Byerly]

    Municipal Employees Retirement System of Michigan raised its holdings in Fiserv Inc (NASDAQ:FISV) by 146.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 26,800 shares of the business services provider’s stock after purchasing an additional 15,920 shares during the quarter. Municipal Employees Retirement System of Michigan’s holdings in Fiserv were worth $1,986,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Shane Hupp]

    Fiserv (NASDAQ:FISV) last released its quarterly earnings data on Thursday, February 7th. The business services provider reported $0.84 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.84. Fiserv had a return on equity of 47.56% and a net margin of 20.39%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the firm posted $0.71 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts expect that Fiserv Inc will post 3.46 EPS for the current fiscal year.

    ILLEGAL ACTIVITY NOTICE: “Checchi Capital Advisers LLC Has $581,000 Position in Fiserv Inc (FISV)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at www.tickerreport.com/banking-finance/4163064/checchi-capital-advisers-llc-has-581000-position-in-fiserv-inc-fisv.html.

    Fiserv Profile

  • [By Stephan Byrd]

    Rathbone Brothers plc purchased a new stake in Fiserv Inc (NASDAQ:FISV) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 3,500 shares of the business services provider’s stock, valued at approximately $259,000.

  • [By Stephan Byrd]

    Fiserv (NASDAQ:FISV)’s share price reached a new 52-week high and low during trading on Monday . The stock traded as low as $74.61 and last traded at $74.25, with a volume of 72911 shares changing hands. The stock had previously closed at $73.51.

  • [By Max Byerly]

    Fiserv Inc (NASDAQ:FISV) – Wedbush boosted their FY2018 earnings per share estimates for shares of Fiserv in a report released on Monday, August 13th. Wedbush analyst M. Katri now anticipates that the business services provider will earn $3.14 per share for the year, up from their previous estimate of $3.12. Wedbush also issued estimates for Fiserv’s Q4 2018 earnings at $0.84 EPS, Q3 2019 earnings at $0.87 EPS, Q4 2019 earnings at $0.91 EPS and FY2019 earnings at $3.47 EPS.

Top 10 Performing Stocks For 2019: Avid Technology Inc.(AVID)

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Avid Technology Inc  (NASDAQ:AVID)Q4 2018 Earnings Conference CallMarch 14, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Avid Technology (AVID)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Avid Technology (AVID)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks For 2019: RELX N.V.(RENX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Relx (NYSE:RENX) was upgraded by research analysts at Barclays to a “buy” rating in a report released on Monday.

    RENX has been the subject of several other research reports. Zacks Investment Research raised shares of Relx from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. UBS Group cut shares of Relx from a “neutral” rating to a “sell” rating in a research note on Thursday, June 14th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $23.00.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Relx (RENX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com